Evaluating conservative management for retained products of conception and enhanced myometrial vascularity
A Prospective Study Evaluating the Impact of Conservative Management on Retained Products of Conception and EMV
This study is testing if gentle treatments for people with leftover pregnancy tissue after a miscarriage can help them recover naturally over two menstrual cycles.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Sex | Female |
| Sponsor | Fu Xing Hospital, Capital Medical University Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT06862089 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the therapeutic effects of conservative management on individuals with retained products of conception (RPOC) and enhanced myometrial vascularity (EMV). Participants who have recently experienced a miscarriage or delivery will receive conservative treatments such as mifepristone or expectant management. The study will evaluate the efficacy of these treatments in achieving natural resolution of RPOC over two menstrual cycles. The primary focus is to determine if combining conservative management with EMV can lead to improved outcomes.
Who should consider this trial
Good fit: Ideal candidates include individuals with a recent history of miscarriage or delivery who are willing to undergo conservative management.
Not a fit: Patients experiencing heavy vaginal bleeding or those with active infections or severe organ dysfunction may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a non-invasive treatment option for patients experiencing retained products of conception.
How similar studies have performed: While there is limited information on similar studies, the approach of conservative management for RPOC is gaining interest, though its efficacy remains to be fully established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Recent history of miscarriage or delivery (within the past 8 weeks) * Strong willingness to undergo conservative management * Hemodynamically stable * Signed informed consent form Exclusion Criteria: * Heavy vaginal bleeding (requiring immediate surgical intervention) * Active pelvic or systemic infection (e.g., fever \>38°C, elevated CRP/WBC) * Severe dysfunction of vital organs (heart, liver, or kidney) * Known drug allergies or contraindications to proposed medications (e.g., misoprostol intolerance) * Suspected ectopic pregnancy or gestational trophoblastic disease (confirmed by ultrasound or β-hCG levels) * Placenta accreta spectrum disorders diagnosed during current pregnancy * History of uterine artery embolization
Where this trial is running
Beijing
- Hysteroscopy Center, Fuxing Hospital, Capital Medical University — Beijing, China (Recruiting)
Study contacts
- Study coordinator: Rui Huang
- Email: blueberry0801@foxmail.com
- Phone: +86 18610317613
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.